New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomide

HOUSTON, TX, USA I June 12, 2023 I Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces the presentation of a poster related to the company’s novel molecular glue, SP-3164, at the European Hematology Association 2023 Hybrid Conference, which was held in Frankfurt, Germany and virtually June 8-11, 2023.

Research presented on June 9, 2023 by Aundrietta Duncan, Ph.D., director of non-clinical development at Salarius, in a poster titled “A Novel Cereblon-Binding Molecular Glue, Sp-3164, Shows Preclinical Activity In Non-Hodgkin Lymphomas” and available here, demonstrated:

  • Potent degradation of Ikaros and Aiolos (I/A) in peripheral blood mononuclear cells (PBMC) within 2 hours of dosing, which increased in a dose- and time-dependent manner over 24 hours.
  • SP-3164 does not negatively impact PBMC at clinically relevant concentrations up to 96 hours post-treatment.
  • In addition to having direct antitumor effects, SP-3164 also induces an anticancer immunomodulatory effect as demonstrated through the induction of cytokine secretion in human T cells following treatment.

In addition, new quantitative proteomic data revealed that in Jeko-1 (lymphoma) cells, SP-3164 induces twice the degradation of target proteins I/A at 1/10th the dose of lenalidomide, providing further support for the development of SP-3164 in relapsed refractory non-Hodgkin lymphoma.

“We continue to advance our body of knowledge for SP-3164, with data generated to date demonstrating potent antitumor activity that supports our plans to file an Investigational New Drug application with the U.S. Food and Drug Administration in the coming weeks. We plan to begin a Phase 1 study in the second half of the year,” said David Arthur, president and chief executive officer of Salarius. “Our first therapeutic target is blood cancer, and we are excited to embark on a potential new treatment option for these patients.”

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options. Salarius’ product portfolio includes seclidemstat, Salarius’ lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader that is being developed as a treatment for non-Hodgkin lymphoma.

Seclidemstat has received fast track, orphan drug and rare pediatric disease designations for Ewing sarcoma from the U.S. Food and Drug Administration and is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with an investigator-initiated Phase 1/2 clinical study in hematologic cancers at MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing program and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). SP-3164 is currently in IND-enabling studies and is anticipated to enter the clinic in 2023.

SOURCE: Salarius Pharmaceuticals